Longevity medicine or health supplement? Jindawei is obliged to clarify misunderstandings
Beijing News Illustration/Chen Dong
Company observation
A company's products hit the edge, chasing ups and downs in the capital market, not only cheating consumers, but also investors.
"Start your journey against age."
Opened the Tmall official flagship store of Doctor's Best (hereinafter referred to as DRB), a US holding subsidiary of the listed company Kingway, and a bottle of 1,500 yuan, said to be able to "anti-aging" NMN product was placed in the most prominent position. However, according to the investigation of the Beijing News Shell Finance and Economics reporter, this "longevity medicine", which claims to be able to delay aging, has not completed all human clinical trials, and it is only a dietary supplement.
However, this still makes the listed company Jindawei (002626.SZ) a full harvest: from July 9th to July 15th, Jindawei has five consecutive daily limits, and the total market value has risen from 16.337 billion yuan which closed on July 8. At the closing price of 26.318 billion yuan on July 15, the market value increased by nearly 10 billion.
On July 19, the Shenzhen Stock Exchange issued an inquiry letter. The company was asked about the specific production and sales of NMN products on sale and the approval or certification of the product in the United States. In response to the inquiry letter from the Shenzhen Stock Exchange, Jindawei stated that this product has passed "NSF cGMP (dietary supplement) certification and NSF cGMP (sports nutrition) certification in the United States, and implements the US dietary supplement FDA21CFR111,117 standard." Said, "DRB has not made a clear commitment to the actual utility of the product, and has clearly indicated that it will not be used to diagnose, treat, cure or prevent any disease."
In other words, behind the skyrocketing share price, this highly sought-after NMN "longevity medicine" is actually only a dietary supplement in the official certification and is far from an anti-aging drug.
However, judging from the cautious response of Jindawei to the Shenzhen Stock Exchange, it is quite different from the style of the slogan on its product page: anti-aging and anti-aging. These clear utility expressions are placed in the most prominent position, "I feel sleep is relieved." Many people have a lot of energy", "The product is really good, mainly feeling that the stomach and intestines are improved, the eyes are improved, and the dryness is no longer." After-sales reviews of similar advertising slogans are also flooding some e-commerce platforms. This makes it easy for consumers to think that this is a "longevity medicine" that can rejuvenate and rejuvenate, rather than a health product whose effects have yet to be verified.
For those consumers who pay more attention to product pages, Jindawei's "cautious" statement in the securities market obviously cannot help them make correct judgments when they consume.
In recent years, many of the pharmaceutical stocks that have been hyped up have been trapped in a whirlpool of false propaganda. According to previous incomplete statistics from the media, in the past ten years, at least 9 listed pharmaceutical, medical, and health care products companies have been exposed for false advertising and have fallen into trouble, including Aier Ophthalmology and Wohua Pharmaceutical , Jiaotong University Onlly, Dongbao Bio, Jiudian Pharmaceutical, Tonghua Jinma, Sharp Aisi and other companies.
The performance of listed companies in the product market is directly related to the company's attention in the capital market, which is understandable. However, if a company’s products hit the edge and catch ups and downs in the capital market, it will not only pit consumers, but also investors.
On March 1, 2020, the newly revised "Securities Law of the People's Republic of China" ("The New "Securities Law") came into effect. The new "Securities Law" provides further clear provisions on the false statements of listed companies when disclosing information. It states that "the obligor of information disclosure fails to disclose information in accordance with the regulations, or the publicly announced securities issuance documents, periodic reports, temporary reports and other If there are false records, misleading statements, or major omissions in the information disclosure materials, which cause investors to suffer losses in securities transactions, the information disclosure obligor shall be liable for compensation." Judging from the current response of Jindawei, it has not really responded to the doubts of the market.
In accordance with Article 20 of Chapter 4 of the "Guidelines for Social Responsibility of Listed Companies on the Shenzhen Stock Exchange" previously issued by the Shenzhen Stock Exchange, listed companies should be honest and trustworthy with suppliers, customers and consumers, and must not rely on false publicity and advertising for profit. Therefore, whether it is for investors or consumers, Jindawei has the responsibility and obligation to give more responses to clarify misunderstandings.
□Beixue (financial commentator)